---
id: biotech-and-genomics
name: BioTech & Genomics
family: technological
tier: active
url: https://futuremap.talin.digital/e/biotech-and-genomics/
license: CC-BY-NC-4.0
---

# BioTech & Genomics

## Maturity
4/5 — Sequencing capability is effectively mature and its cost curve is the steepest in this book; clinical translation is far behind, and the score is the blend.

Source: NHGRI Genome Sequencing Program cost data (Wetterstrand) — ~$95m per genome in Sept 2001 to ~$500 by 2022; sub-$1,000 only from ~2019 (2001–2022)

## What it is
Reading, interpreting and applying biological information — sequencing, diagnostics, and the biological engineering built on them.

## What it does
It converted biology from an observational science into an engineering one. Sequencing cost fell faster than semiconductor cost over the same period, which is the sharpest exponential in this book.

## Common misconception
That falling sequencing cost translates into clinical benefit at the same rate. Interpretation, evidence generation and clinical integration are each far slower, and each is the binding constraint somewhere.

## Steepens
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — large
- Precision Everything (precision-everything) — large
- Zoonotic and Antimicrobial Resistance Risk (zoonotic-and-antimicrobial-resistance-risk) — moderate
- Food System Transformation (food-system-transformation) — moderate

## What would change its gradient
- Interpretation at population scale, which requires diverse reference data
- Clinical evidence generation, which runs on trial timescales
- Reimbursement, which decides what reaches patients
